No Action as Yet on Rimonabant in Europe.

The European Business organisation for the Appraisal of Medical Products (EMEA) did discuss the weight-loss drug rimonabant (Acomplia, Sanofi Aventis) at its June coming together held this week, but it has not reached any conclusions on whether any further regulatory state is needed on the trade good. The business will continue to recapitulation data on the drug and will discuss the mental object again at its gathering next time period, to be held on July 16-19.


This follows the unanimous human action of a US content travail for rimonabant by the FDA's Endocrinologic and Metabolic Drugs Advisory Commission last week. The FDA commission said that more detailed long-term preventative assemblage with larger semantic role number was needed with affection to neurological and psychiatric side effects that have been associated with the drug, including seizures, Great Depression, anxiousness, insomnia, hostility, and suicidal thoughts.